ArticleCureus2025
Perioperative and Mid-term Outcomes of the Ankura Thoracic Stent Graft in Aortic Arch Pathologies With Open and Endovascular Perfusion of Supra-Aortic Branches: A Retrospective Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThis study reports on the perioperative and mid-term outcomes of a novel thoracic stent graft in aortic arch pathologies.
methodsFrom January 2017 to May 2023, all patients treated with Ankura (Lifetech Scientific, Shenzhen, China) thoracic endograft combined with extra-anatomic and/or endovascular perfusion of supra-aortic branches at two university vascular centers were retrospectively reviewed. Indications for treatment included aneurysm, dissection, penetrating ulcer, intramural hematoma, traumatic rupture of the aortic arch and endoleak type Ia (Ia EL) of previous endovascular repair of the descending thoracic aorta. Perioperative and late causes of morbidity and mortality were captured. Patients' follow-up was obtained by computed tomography angiography at one month, six months, one year and then annually. The primary endpoint of the study was technical success, and secondary endpoints included aortic-related complications and all-cause mortality during follow-up.
resultsAortic arch repair with Ankura thoracic endograft was performed in 30 patients. Mean age was 69.3 years (53-85 years), and male was the prevalent gender (25 patients, 83%). According to Ishimaru classification, Ankura stent graft was deployed at zone 2 in 21 patients (70%), at zone 1 in eight patients (26.6%) and at zone 0 in one patient (3.3%). Technical success was 94%. Type Ia EL was detected at two patients (6.6%). Perioperative morbidity and mortality were 6.6% and 3.3%, respectively. Mean follow-up was 22.03 months (range: 1-24 months). The aortic reintervention rate was 0%, and all-cause mortality was 16.6%.
conclusionAnkura thoracic endograft showed satisfactory results with high technical success and low aortic-related complications in our study. Larger studies are necessary to establish the safety and efficacy of Ankura endograft in aortic arch pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.